Neumora Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Neumora Therapeutics

12/05/2025 22:01

Neumora Therapeutics Inc NMRA.OQ reported a quarterly adjusted loss of 42 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -34 cents.  The mean expectation of seven analysts for the quarter was for a loss of 37 cents per share. Wall Street expected results to range from -46 cents to -33 cents per share.

Reported revenue was zero​; analysts expected zero.

Neumora Therapeutics Inc's reported EPS for the quarter was a loss of 42 cents​.

The company reported a quarterly loss of $67.99 million.

Neumora Therapeutics Inc shares had fallen by 33.7% this quarter and lost 93.7% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 15.3% in the last three months.​

In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy," 5 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

Wall Street's median 12-month price target for Neumora Therapeutics Inc is $4.00

This summary was machine generated from LSEG data May 12 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.37
-0.42
Missed
Dec. 31 2024
-0.45
-0.37
Beat
Sep. 30 2024
-0.39
-0.45
Missed
Jun. 30 2024
-0.37
-0.37
Met